Elena-Laura Budusan

Dr. Elena-Laura Budusan serves as a Postdoctoral Research Fellow at the University of Queensland's Institute for Molecular Bioscience (IMB), where she investigates ion channel pharmacology using venom-derived peptides as molecular probes. Her work bridges basic science and therapeutic development, with emphasis on acid-sensing ion channels (ASICs) implicated in pain and stroke pathologies.

Her primary research focuses on characterizing venom peptides from spiders (e.g., Hi1a, Hc3a) and snakes (e.g., mambalgin-3) that modulate ASIC function. Through multidisciplinary approaches combining peptide chemistry, electrophysiology, and molecular modeling, she elucidates structure-activity relationships to develop novel analgesics and neuroprotective agents. Current projects include optimizing peptide stability, evaluating therapeutic efficacy in stroke models, and exploring mechanisms of ion channel desensitization.

Analysis of her 2021-2024 publications reveals a cohesive trajectory from molecular characterization (e.g., mambalgin-3's interaction with ASIC1 variants) to translational applications (e.g., Hi1a's effects in stroke models). Her work demonstrates progression from in vitro mechanistic studies to in vivo validation, highlighting venom peptides' potential as therapeutic leads for neurological disorders.

No scientific awards or fellowships are documented in the provided materials.

Dr. Budusan is available for research supervision and collaborates extensively within IMB's Venom Therapeutics Laboratory. Her work leverages institutional resources including automated patch clamp facilities and peptide synthesis platforms, though specific grant funding details are not disclosed in the source texts.

She operates within IMB's collaborative ecosystem under the mentorship of Professor Lachlan Rash and Professor Glenn King, contributing to Australia's internationally recognized venom research program. Her team employs cutting-edge techniques from CRISPR-based lineage tracing to in-silico structure prediction, positioning her work at the intersection of toxinology and drug discovery.